Anticoagulants such as the defence iron-binding protein, lactoferrin naturally present in exocrine secretion or heparin used to impede the COVID-19-induced hypercoagulability have been assessed for their anti-SARS-CoV-2 activity. The gene discussed is LTF; the disease is thrombophilia.